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Ras pathway signaling is a critical virulence determinant for pathogenic fungi. Localization
of Ras to the plasma membrane (PM) is required for Ras network interactions supporting
fungal growth and virulence. For example, loss of Aspergillus fumigatus RasA signaling
at the PM via inhibition of palmitoylation leads to decreased growth, altered hyphal
morphogenesis, decreased cell wall integrity and loss of virulence. In order to be
properly localized and activated, Ras proteins must transit a series of post-translational
modification (PTM) steps. These steps include farnesylation, proteolytic cleavage of
terminal amino acids, carboxymethylation, and palmitoylation. Because Ras activation
drives tumor development, Ras pathways have been extensively studied in mammalian
cells as a potential target for anti-cancer therapy. Inhibitors of mammalian Ras interactions
and PTM components have been, or are actively being, developed. This review will focus
on the potential for building upon existing scaffolds to exploit fungal Ras proteins for
therapy, synthesizing data from studies employing both mammalian and fungal systems.
Keywords: Ras protein, G domain, hypervariable region, post-translational modifications, spatio-temporal
regulation, fungal pathogenesis, antifungal therapeutics
INTRODUCTION
Aspergillus fumigatus is the most common fungal pathogen of
invasive aspergillosis in immunocompromised patients. Despite
the introduction of several antifungal drugs, infections related to
invasive aspergillosis are usually severe and fatal (Latge, 1999).
Therefore, there is an increasing demand for new drugs against A.
fumigatus infections, and thereby identification of target proteins
for therapeutic drug design.
Ras-mediated signaling pathways play key roles in regulating
cell responses to different stresses via a wide range of effector pro-
teins (for more information, refer to Rajalingam et al., 2007). In
pathogenic fungi, Ras signaling pathways control virulence in host
cells (reviewed in detail in Fortwendel, 2012). Therefore Ras pro-
teins, and their effectors, represent potential targets of interven-
tion for novel antifungal therapies. Due to their role in tumor for-
mation, mammalian Ras post-translational modification (PTM)
pathway proteins have been studied in detail for their potential
as targets for anticancer therapeutics (refer to Downward, 2003;
Adjei and Hidalgo, 2005; Spiegel et al., 2014). In this minireview,
we discuss these studies in the context of development of antifun-
gal therapy. Since RasA is the major Ras protein in A. fumigatus,
this brief review focuses on the RasA signaling pathway.
A. Fumigatus Ras PROTEINS
Ras proteins are low molecular weight monomeric G-proteins,
which localize to the plasma membrane (PM) and exhibit GTPase
activities (Wennerberg et al., 2005). They are induced by extra-
cellular stimuli and function primarily as signal mediators for
several downstream cascades. Such cascades activate transcription
factors, which control a wide range of cellular processes such
as cell growth, division, differentiation and survival (Weeks and
Spiegelman, 2003). In contrast to human cells, which typically
express three Ras isoforms (HRas, KRas, and NRas), only two
Ras homologs (RasA and RasB) are produced in A. fumigatus
(Fortwendel et al., 2004). Based on sequence similarity, RasA is
more closely related to the human H-Ras with homologs found in
most eukaryotes. In contrast, RasB is only produced by filamen-
tous fungi (Fortwendel et al., 2004). Both, RasA, and RasB, exhibit
distinct but overlapping roles in conidial germination, mycelial
growth, conidiogenesis, and cell mitosis (Fortwendel et al., 2004,
2005, 2008, 2012). Additionally, both proteins modulate virulence
in A. fumigatus and other pathogenic fungi (Fortwendel et al.,
2005, 2012; Fortwendel, 2012).
DOMAIN STRUCTURE OF Ras PROTEINS
The domain structure of human Ras proteins has been reviewed
in detail previously (Sprang, 1997; Vetter and Wittinghofer, 2001;
Wittinghofer and Vetter, 2011). Briefly, the approximately 190-
amino acid protein is divided into 165 highly conserved amino
acids (90–100% identical) at the N-terminus (known as the
G domain or GTPase domain) and a C-terminal hypervari-
able region (HVR) that encompasses the remaining amino acids
(Hancock, 2003). In the next sections, we will discuss the domain
structure of both regions and their role in mediating Ras activa-
tion, transmembrane localization and cell signaling.
THE G DOMAIN FACILITATES PROTEIN CONFIRMATION AND
DOWNSTREAM SIGNALING
Numerous biochemical, molecular and structural studies, involv-
ing both yeast and mammalian cells, have shown that the
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G domain of Ras-like proteins houses the amino acid sequences
required for binding guanine nucleotides [i.e., guanosine diphos-
phate (GDP) and guanosine triphosphate (GTP)], GTPase-
activating protein (GAP), guanine nucleotide exchange factor
(GEF), and downstream effectors (Ahearn et al., 2012). The G
domain is organized into six β sheets and five α helices. Addition-
ally, two loop regions, designated switch I and switch II, mediate
Ras transformation between its two interchangeable activity states
via conformational change during binding of guanine nucleotides
(Vetter and Wittinghofer, 2001).
The Ras activation mechanism involves GEF proteins, which
promote the release of GDP. GTP, which exists in the cytoplasm
at concentrations 10 times higher than that of GDP, binds to
the GDP-free form of Ras. GTP association with Ras releases
energy, which changes protein conformation at the switch I and
II regions. This transforms Ras to the active state and allows
binding of the effector proteins to its G domain. Active Ras
proteins are negatively regulated by GAP proteins. Binding of
GAP to Ras protein increases its intrinsic GTPase activity 105
fold and hydrolyzes GTP to GDP. The hydrolysis of GTP depletes
the released energy, causing conformational changes at the switch
domains, and subsequently releasing the effector (Vetter and Wit-
tinghofer, 2001; Wennerberg et al., 2005; Kyriakis, 2009; Ahearn
et al., 2012; Prior and Hancock, 2012).
THE HVR GOVERNS Ras MEMBRANE LOCALIZATION AND ANCHORING
The HVR of RasA homologs is divided into two regions: an
anchor and a linker. The anchor region is highly conserved among
Ras isoforms and is composed of a CAAX box—where C is
cysteine, AA are two aliphatic amino acids, and X is any amino
acid—and a palmitoylation motif (Gao et al., 2009).
The anchor plays an essential role in Ras subcellular trafficking
and membrane localization. Protein trafficking and subsequent
membrane association of many proteins is typically mediated
by hydrophobic transmembrane domains. However, Ras proteins
lack such domains, and therefore the protein undergoes several
PTMs at the CAAX box and the palmitoylated cysteine motif
which convert the HVR to a hydrophobic, membrane-associated
domain (Figure 1A) (Takai et al., 2001; Hancock, 2003; Larsen
et al., 2006; Iwasaki and O¯mura, 2007).
Ras PTM mechanisms have been studied in detail in human
and yeast cells. In spite of lack of similar studies in A. fumigatus,
homologous proteins have been identified in the A. fumigatus
genome (Figure 1B), implying conservation of RasA PTM pro-
cesses in Aspergillus species. The first step of the Ras PTM series is
prenylation, which is the process of covalent addition of a farnesyl
(farnesylation) or geranylgeranyl group (geranylgeranylation) at
the cysteine residue of the CAAX box via farnesyl transferase
(FT) or geranylgeranyl transferases (GGT I and II), respectively
(Berndt and Sebti, 2011). Prenylation of the CAAX box facilitates
the association of Ras protein to the endoplasmic reticulum
(ER) membrane (Omerovic et al., 2007). At the ER membrane,
the farnesylated (or geranylgeranylated) Ras protein is further
processed by AAX cleavage via type I (Ste24) and type II CAAX
prenyl endopeptidase (Rce1) (Manolaridis et al., 2013).
The remaining prenylated cysteine residue of the CAAX box is
then methylated by isoprenylcysteine carboxyl methyltransferase
(ICMT) in the ER (Chiu et al., 2004). Prenylation, proteolysis,
and methylation suffice weak binding of the CAAX motif cysteine
residue to the ER membrane. Such unstable association causes
Ras to encounter a constant exchange between the ER membrane
and the cytoplasm (Greaves and Chamberlain, 2007). Therefore,
a second moiety is required to stabilize Ras association to the
ER membrane. Such a signal varies and can be a lysine polybasic
domain in K-Ras(B), a single palmitoylation site in N-Ras and K-
Ras(A), or a double palmitoylation site in H-Ras (Hancock et al.,
1989, 1990). Palmitoylation, specifically S-palmitoylation, is the
addition of palmitate to the cysteine residue(s) via thioester bond
(Smotrys and Linder, 2004; Wan et al., 2007). In Ras proteins,
palmitoylation cysteines are located in the anchor region and are
adjacent to the CAAX box cysteine residue (Linder and Desch-
enes, 2007). Palmitoylated Ras is transported from the Golgi to
the PM via the exocytic vesicular pathway (Goodwin et al., 2005).
Unlike prenylation, palmitoylation is a reversible step, as Ras can
be depalmitoylated via thioesterase on the PM. Depalmitoylated
Ras recycles back to the Golgi via a non-vesicular pathway. This
cycle of palmitoylation and depalmitoylation is used by the cell
to avoid unnecessary accumulation of Ras proteins on the PM
(Goodwin et al., 2005; Salaun et al., 2010).
In fungi, the amino acid composition of the anchor region
varies among species in different ways. First, the number of
cysteine residues in the palmitoylation region varies from one
cysteine in S. cerevisiae, S. pombe, and Candida albicans; to two
cysteine residues in Cryptococcus neoformans and other filamen-
tous fungi such as A. fumigatus. Second, variations in the anchor
region might exist between different Ras homologs within one
fungal species. For example, unlike RasA, A. fumigatus RasB does
not contain the palmitoylation cysteine residues. Although no
experimental evidence for RasB localization exists, the differences
in anchor region amino acid sequence might indicate different
subcellular localizations of RasA and RasB (Fortwendel, 2012).
Ras-MEDIATED FUNGAL MORPHOGENESIS AND VIRULENCE
DEPEND ON THE SPATIO-TEMPORAL REGULATION OF Ras
ACTIVITY
Like their human counterparts, the cellular functions of fungal
Ras GTPases depend on the spatio-temporal regulation of the
protein on the PM. Understanding the spatio-temporal organiza-
tion of RasA has been a necessary step in selecting potential targets
that are predicted to interfere with its ability to properly transmit
signals for growth, stress response and virulence. The following
sections will briefly summarize our current knowledge of RasA
spatial and temporal regulation mechanisms.
THE TEMPORAL REGULATION OF RasA ACTIVITY
The essential role of temporal activation of RasA has been inves-
tigated by comparing the phenotype of A. fumigatus mutants that
express dominant negative RasA (DNrasA) or dominant activate
RasA (DArasA) to that of a rasA (1rasA) deletion mutant. The
DNrasA and DArasA mutants provide the ability to study the phe-
notypic effects of improper temporal inactivation or activation
of RasA, respectively, during development. DNrasA, and 1rasA
strains show similar phenotypes (i.e., delayed in germination),
whereas the DArasA mutant initiates germination in the absence
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FIGURE 1 | Conservation of the Ras post-translational modification
pathway in Aspergillus fumigatus. (A) Ras proteins transit a series of
post-translational modifications to reach the plasma membrane. These
include: (1) farnesylation of cytoplasmic Ras on a conserved cysteine residue
by a dual subunit, protein farnesyltransferase enzyme complex; (2) cleavage
of the C-terminal CAAX motif; (3) methylation of the processed C-terminus;
and (4) palmitoylation of conserved cysteine residues upstream of the CAAX
motif. Farnesylation is prerequisite for association with the endoplasmic
reticulum, whereas palmitoylation is required for stable association with the
plasma membrane. Inhibitors with activity against these processes in
A. fumigatus include manumycin A and 2-bromopalmitate, targeting
farnesylation and palmitoylation, respectively. FT = farnesyltransferase;
RCE = Ras converting enzyme; ICMT = isoprenylcysteine
carboxymethyltransferase; PAT = palmitoyltransferase. (B) Homologs of the
protein components of the Ras post-translational modification pathway are
shown. Protein lengths in amino acids (aa) are included with the GenBank
accession numbers. Identity (%) was determined using protein alignments in
Lasergene software (DNAstar). For reference, homologs of the yeast pathway
are given in parentheses next to the A. fumigatus Af293 systematic name
(right column).
of a germinant. Additionally, mycelia of all three strains grow
slower than wild type and exhibit defects in polarity maintenance.
Although constitutive Ras activation delays germ tube formation
and reduces colony outgrowth, the DArasA mutant also displays
hyphal swelling and spontaneous lysis during fully polarized
growth (Fortwendel, 2012). These data show the importance of
temporal regulation of RasA activity for proper hyphal morpho-
genesis, since the inability to modulate RasA activity during devel-
opmental progression causes abnormalities in fungal growth.
THE SPATIAL REGULATION OF RasA SIGNALING
In addition to the previously described temporal regulation,
spatial regulation of Ras signaling plays an essential role in
RasA function. Evidence for the cellular mechanisms that control
A. fumigatus RasA PTM and localization was obtained from
subcellular localization analyses of RasA using GFP tagging.
Similar to human Ras, RasA localizes to the PM of A. fumiga-
tus. However, when RasA farnesylation is blocked by exchange
mutagenesis of the CAAX box cysteine residue (C210) to ser-
ine, RasA aborts the PM localization and accumulates in the
cytoplasm. Additionally, expression of RasA in an A. fumiga-
tus deletion strain of the putative palmitoyltransferase subunit
gene (1erfD) shows a punctate localization of RasA, implying
palmitoylation of RasA is required for PM localization. Fur-
thermore, mutation of the palmitoylation double cysteine motif
(C206 and C207) to serine mislocalizes RasA to endomembranes.
Phenotype analysis of these mutants showed that A. fumigatus
strains expressing either a non-farnesylated or non-palmitoylated
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RasA exhibit a full or partial 1rasA phenotype, respectively
(Fortwendel et al., 2012; Norton and Fortwendel, 2014). Con-
sistent with these data, similar results have been obtained in
other pathogenic fungi. For example, in C. neoformans, farne-
sylation and palmitoylation are both required for normal Ras1
localization and morphogenesis (Nichols et al., 2009). In C. albi-
cans, both PTMs are required for localization, but farnesylation
plays the greater role in Ras-mediated growth and morphogen-
esis (Piispanen et al., 2011). Taken together, these data support
the importance of RasA PTM processes for fungal growth and
virulence.
APPROACHES FOR DEVELOPING Ras-TARGETED
ANTIFUNGAL THERAPEUTICS
Mammalian Ras signaling pathways have been the target of exten-
sive research for developing anticancer therapeutics. This accu-
mulated knowledge could be translated into novel strategies to
treat Aspergillus infections since the mechanisms of Ras activation
and PTMs are shared by both human and fungi. The development
of Ras-targeted anticancer therapy has focused on: (1) targeting
Ras proteins directly, (2) blockade of Ras upstream and down-
stream signaling pathways, and (3) inhibition of Ras PTMs. There
are many Ras inhibitors that have tested in mammalian cell as
anticancer therapeutics. Details on specific successes and failures
have been reviewed extensively (Adjei and Hidalgo, 2005; Berndt
et al., 2011; Spiegel et al., 2014). Although all three of these have
been pursued as potentially viable channels for inhibition of Ras
function, most progress has been achieved in the development of
anti-Ras compounds targeting the PTM pathway. In the following
section, we will briefly describe these approaches, focusing mainly
on inhibition of Ras PTMs and the published data that support
this pathway as a potential anti-Aspergillus therapeutic target.
TARGETING Ras PROTEINS AND Ras PROTEIN INTERACTIONS
In A. fumigatus, RasA modulates fungal pathogenesis and has
been considered an attractive target for antifungal agents. Directly
targeting Ras proteins for anticancer therapies has proven a diffi-
cult task. For example, inhibition of Ras-GTP binding is difficult
to achieve, since the Ras-GTP interaction is very high affinity,
occurring in the picomolar range (Gysin et al., 2011). However,
recent approaches have generated small molecules that inhibit K-
Ras activation (Maurer et al., 2012). This method relied on in-
depth structural analyses of the K-Ras protein, the level of which
have not been accomplished for any fungal Ras protein. As such,
the applicability of such inhibitors remains unknown for fungal
Ras proteins.
In general, fungal Ras proteins appear to share similar sig-
naling mechanisms with their human homologs, and therefore
inhibitors of these signaling events might also have great potential
for thwarting invasive fungal infections. Examples of these are
protein kinases that modulate downstream Ras signaling path-
ways. Several kinase inhibitors have been applied successfully to
treat cancer (reviewed in detail by Downward, 2003), however,
these molecules have not been tested in models of fungal infec-
tion. Although the signaling mechanisms are similar between
humans and fungi, a deeper understanding of the biochem-
istry underpinning Ras-mediated signaling in pathogenic fungi is
required for the identification of fungal-specific, selective targets
in this area.
INHIBITION OF Ras PTM
Inhibition of farnesylation
In contrast to the limited number of therapeutics directly tar-
geting Ras proteins, multiple compounds are being developed
and employed to inhibit steps in the PTM pathway of human
Ras proteins. Importantly, the individual elements of the PTM
pathway are conserved between humans and fungal pathogens,
the first step of which is the lipidation of Ras with a farnesyl moi-
ety (Figure 1B). There are several farnesyl transferase inhibitors
(FTIs) that are used or being clinically tested for use as anticancer
agents (described in detail by Appels et al., 2005). The antifungal
activities of some of these FTIs have been evaluated against several
pathogenic fungi. For example, when the wild type strain of C.
neoformans was treated with six different FTIs, one inhibitor,
i.e., Manumycin A, showed inhibitory activities comparable to
Amphotericin B—an antifungal agent. Additionally, when a C.
neoformans mutant that lacks the cell wall capsule, i.e., cap59
mutant, was used, two additional FTIs, namely ethylenediamine
inhibitor #2 and tipifarnib, showed elevated inhibitory activities.
Interestingly, treatment of C. neoformans with high concentra-
tions of Manumycin A caused a shift in Ras1 localization from the
PM to the cytosol (Hast et al., 2011). Similar experiments have
been carried out to study antifungal activities of Manumycin A
against several species from Aspergillus and Candida. Compared
to C. neoformans, the FTI minimal inhibitory concentrations
(MIC) were 80–160-fold and 5–10-fold higher for Aspergillus
and for Candida, respectively. (Hast et al., 2011; Qiao et al.,
2013). However, it is unclear whether such differences in MIC
are caused by fungal resistance to Manumycin A; or variations in
experimental procedure, media composition, or pH of the media.
In a similar experiment, the inhibition of protein farnesylation
in C. albinans by farnesyl transferase inhibitor III (FPT inhibitor
III) blocked the development of yeast to hyphae (McGeady et al.,
2002), which is a Ras-mediated virulence step (Cutler, 1991;
Feng et al., 1999). Additionally, FPT Inhibitor III blocks hyphal
differentiation in a dose-dependent manner in C. neoformans
(Vallim et al., 2004).
To better understand the protein–protein interactions between
FT and their inhibitors (FTIs), structural studies of inhibitor-
bound A. fumigatus and C. neoformans FT were compared to
their human homolog. These studies revealed that the substrate-
binding groove residues are highly conserved between human
and fungal FT, while the product exit groove displays a high
sequence divergence. Importantly, these studies reveal fungal-
specific attributes of the highly conserved Ras PTM pathway. For
example, both grooves are wider in fungal FT in comparison
to their human homolog, causing weaker binding activities of
inhibitors toward Aspergillus FT in comparison to human FT
(Hast et al., 2011; Mabanglo et al., 2014). Therefore, modification
of anticancer FTIs is required for optimal antifungal efficiency.
Re-purposing FTIs developed for anticancer treatments may rep-
resent a novel area for antifungal drug development.
In addition to targeting Ras farnesylation, mapping the
fungal farnesylome, i.e., proteins that are farnesylated by
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farnesyltransferase, will open the door for numerous potential
drug targets. One example is the Ras-related protein, Rheb, which
is, like Ras proteins, farnesylated before transmembrane localiza-
tion (Clark et al., 1997). The cellular functions of mammalian
Rheb are inhibited by cell treatment with FTI (Castro et al., 2003).
In A. fumigatus, the Rheb homolog, i.e., RhbA, plays an important
role in fungal pathogenesis and vegetative growth. An A. fumi-
gatus rhbA deletion mutant, 1rhbA, exhibits impaired virulence
in mouse model and reduced growth on minimal media sup-
plemented with poor nitrogen sources. Additionally, this strain
displays higher sensitivity to the rapamycin antibiotic, which
inhibits TOR kinases (Panepinto et al., 2003). Taken together, this
suggests that fungal Rheb, i.e., Rhb, could serve as potential target
for antifungal therapy.
Inhibition of palmitoylation
Palmitoylation is another putative target for antifungal therapeu-
tics since RasA palmitoylation is important for mycelial polarized
growth and virulence. Targeting Ras palmitoylation is still at
the beginning stages as an anticancer therapeutic. Palmitoylation
inhibitors have only recently been developed and have not yet
been employed in disease models (reviewed in Chavda et al.,
2014). To our knowledge, only one study assessed the potential
of inhibition of RasA palmitoylation as antifungal target. In
this study, blocking RasA palmitoylation in A. fumigatus by 2-
bromopalmitate disrupts RasA transmembrane localization and
reduces fungal growth in liquid culture (Fortwendel et al., 2012).
Therefore, additional studies that aim at designing, developing
and assessing novel compounds that target fungal RasA palmi-
toylation are warranted.
CONCLUSION
The potential for developing antifungal therapeutics by tar-
geting the Ras signaling pathway is a promising avenue of
research. Ras signaling has been studied intensively in humans,
and the accumulated knowledge can be utilized as a scaffold
for the development of antifungal agents with selective tox-
icity. In support of this, the individual components of the
Ras PTM pathway share only partial sequence similarity with
their human homologs (Figure 1B). Additionally, further char-
acterization of Ras regulatory pathways in pathogenic fungi is
necessary to deepen our understanding of fungal growth and
virulence.
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